Preventing the degradation of cGMP by PDE5A inhibitors, such as sildenafil and vardenafil, has become a strategy for the treatment of diseases such as pulmonary hypertension and erectile dysfunction (Corbin et al., 2005; Sandner et al., 2007). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.